HeartKinetics, a Belgian Medtech company specializing in the remote detection and monitoring of patients with heart failure ( HF Company ), is pleased to announce that it has entered Mayo Clinic Platform_Accelerate. The 20-week immersive program is designed to help innovative startups establish credibility and get market ready so that they can spark innovation in health care. Each company receives access to Mayo Clinic’s rich de-identified data sets (more than 7 million patients), validation frameworks, clinical workflow planning, and mentorship.
“We are committed to improving the growth trajectory of early-stage health tech startups,” says Eric Harnisch, vice president of Partner Programs for Mayo Clinic Platform. “All participants will receive guidance on clinical, regulatory, technology, and business decisions. Through these efforts we are building an ecosystem of trusted collaborators to enable new knowledge, new AI solutions, and new technologies.”
“We are thrilled to join the Mayo Clinic Platform_Accelerate program, which is the most renowned database in the world both in terms of quantity of patients available (over 7 million) and quality. HeartKinetics’ vision is that every patient should be able to access a high-quality continuum of care even from the comfort of their home. Through this opportunity, we will validate our AI models and navigate business decisions with the mentorship of Mayo Clinic Platform. These innovations are key to enabling the transition of health care from episodic to continuous quality care that embraces the hospital-at-home model”, explains Pierre-François Migeotte, CEO HeartKinetics.
Since its creation in 2019, HeartKinetics has always put science at the heart of its development. This collaboration is a major step to expand the capabilities of smartphones, smartwatches, and wearables with diagnostics and remote monitoring and to access the U.S. market.
About HeartKinetics
HeartKinetics is a Medtech and Digital Health company specialized in the research, development and commercialization of remote detection and monitoring solutions for heart failure. HeartKinetics is revolutionizing cardiovascular diseases and patient management worldwide thanks to AI-based predictive technology able to intercept heart failure. KINO® is the first solution the company brings to the market (CE mark and FDA agreement are under approval). It combines a mobile self-management app for heart failure patients, a web platform that supports decision-making of healthcare professionals as well as a cloud computing space where the AI-based technology turns data into predictive actionable insights for treatment efficacy.
About KINO®
For cardiologists and general practitioners who need to intercept heart failure, KINO provides a fully integrated patient-centered solution where actionable cardio-haemodynamic data collected with a smartphone is supercharged by AI to detect early signs of decompensation and prevent hospitalizations.
